JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ripley, T. L.
Right arrow Articles by Little, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ripley, T. L.
Right arrow Articles by Little, H. J.

Effects on ethanol withdrawal hyperexcitability of chronic treatment with a competitive N-methyl-D-aspartate receptor antagonist

TL Ripley and HJ Little

Pharmacology Department, Medical School, University Walk, Bristol, England.

The effects of the competitive N-methyl-D-aspartate receptor antagonist DL-(E)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester (CGP39551) on the hyperexcitability produced by withdrawal from chronic ethanol treatment were studied in mice, to which CGP39551 was given chronically with the ethanol. When an interval of 72 or 96 hr was left between the last of the repeated CGP39551 injections and withdrawal from ethanol, the severity of the ethanol withdrawal syndrome was increased. When shorter time intervals were left between the end of the CGP39551 treatment and the ethanol withdrawal, the chronic CGP39551 treatment protected against the withdrawal hyperexcitability. When a single low dose of CGP39551 was given immediately after ethanol withdrawal, the compound protected against the withdrawal hyperexcitability. It is therefore suggested that the protective effects of concurrent chronic treatment with CGP39551, seen when the shorter intervals were allowed, were caused by residual compound. The increased severity of withdrawal, when sufficient time was left for washout of CGP39551, suggests that chronic administration of CGP39551 increased the adaptive changes that cause or contribute to ethanol withdrawal hyperexcitability. The results differ from the previously reported effects of N-methyl-D-aspartate antagonists on ethanol tolerance, because this was reduced by concurrent chronic treatment. They are also in contrast with the effects of chronic dihydropyridine calcium channel antagonists, which decreased both the development of tolerance and the ethanol withdrawal syndrome, when given chronically, concurrently with the ethanol. Cessation of prolonged ethanol intake results in a period of neuronal hyperexcitability, described as the withdrawal or abstinence syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 272, Issue 1, pp. 112-118, 01/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
C. Wang, J. A. Kaufmann, M. G. Sanchez-Ross, and K. M. Johnson
Mechanisms of N-Methyl-D-aspartate-Induced Apoptosis in Phencyclidine-Treated Cultured Forebrain Neurons
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 287 - 295.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. M. E. Wong, D. L. Tauck, E. G. Fong, and J. J. Kendig
Glutamate Receptor-Mediated Hyperexcitability after Ethanol Exposure in Isolated Neonatal Rat Spinal Cord
J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 201 - 207.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics.